Welcome to the official website mall of Shanghai Rainminda Pharmaceutical Technology Co., Ltd

Hello,Please Log In


About Us

Clinical Express | The 7th China Pharmaceutical Investment and Innovation Conference Clinical Data Global First Session

Source:Shohui Organism

Page View:31

Release Time:2023-10-11 18:30:43


OH2 treatment for recurrent adult gliomas 

On March 29, 2023, Professor Li Wenbin, Vice Chairman and Secretary General of the Clinical Research Committee of Brain Neuropharmaceuticals of the China Association for the Promotion of Medical Innovation, and Director of the Cancer Comprehensive Treatment Center of Beijing Tiantan Hospital Affiliated to Capital Medical University, released clinical data on the treatment of adult recurrent glioblastoma using the candidate drug OH2 injection of Binhui Biolytic Oncology Virus at the 7th China Medical Investment and Innovation Conference.


In addition to showing significant therapeutic effects in indications such as melanoma, advanced colorectal cancer, and soft tissue sarcoma, OH2 injection has shown good safety and effectiveness in the treatment of gliomas. The severity of adverse events is often 1/2 grade, and common adverse reactions include influenza like diseases, headache, and fever. Among the 9 patients included in the clinical study, 5 underwent tumor efficacy evaluation. Among them, 1 subject had a 67.5% reduction in lesion size from baseline after 3 doses of medication, which was assessed as PR; Two subjects had stable conditions and were assessed as SD; In the early stages of the experiment, the low-dose group showed good therapeutic effects.

Meanwhile, the study found that within 24 hours after administration and 21 days after administration, OH2 DNA was detected in cerebrospinal fluid samples of PR subjects with 15.52 copies, respectively/ μ L and 169.92 copies/ μ L. OH2 injection infects tumor cells and replicates and proliferates within them. After tumor cell lysis, the progeny virus is released into the cerebrospinal fluid. However, OH2 DNA was not detected in the blood, saliva, and urine samples of the subjects, further confirming the effectiveness and safety of the candidate drug.

In June 2021, Delytact (G47) of the oncolytic herpes simplex virus type I from Daiichi Mitsubishi Corporation in Japan Δ) Approved for the treatment of malignant glioblastoma. Clinical data shows that the one-year survival rate of its treatment for malignant gliomas is as high as 92.3%, which is six times higher than conventional treatment, significantly improving the survival rate of patients with malignant gliomas. As a new method for the treatment of malignant glioblastoma, the candidate drug OH2 injection for Binhui Biolysis II herpes simplex virus has great potential to produce breakthrough therapeutic effects.

Mr. Xu 19025438700

Business Cooperation:
Dr. Xu 19025438700 WeChat:xiaoboo365

Virus Vector:
Manager Shi 15391503730 WeChat:shixiaotai611

Nucleic Acid Products:
Manager Ni 13437112357 WeChat:go-ahead-no-back

Protein Products:
Manager Zhou 18771147489 WeChat:huhu_ai_junjun

Genetic Products:
Manager Wang 13067989761 WeChat:wry12121

Instrument and Equipment:
Manager Ni 13437112357 WeChat:go-ahead-no-back

Test Kit:
Manager Liu 15207178732 WeChat:Q15207178732





*Confirm Password




*Confirm Password